These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 25686113)

  • 81. ΔCT Value of Amplified Refractory Mutation System Predicts Efficacy of EGFR-TKIs in Advanced Non-Small-Cell Lung Cancer: A Multi-Center Retrospective Study.
    Chen M; Huang W; Yang D; Huang J; Li G; Wang X; Xiao N; Zhang W; Guan J; Wang S; Liu L
    Front Mol Biosci; 2021; 8():684661. PubMed ID: 34692766
    [No Abstract]   [Full Text] [Related]  

  • 82. [Models of oncogenesis: an endless world?].
    Larsen CJ
    Bull Cancer; 2013 Jun; 100(6):555-60. PubMed ID: 23719507
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Intratumor heterogeneity: origins, clinical significance and optimal strategies for cancer treatment.
    Mangano A; Lianos GD; Mangano A; Boni L; Dionigi G
    Future Oncol; 2015; 11(4):561-4. PubMed ID: 25686113
    [No Abstract]   [Full Text] [Related]  

  • 84. Adapting clinical paradigms to the challenges of cancer clonal evolution.
    Murugaesu N; Chew SK; Swanton C
    Am J Pathol; 2013 Jun; 182(6):1962-71. PubMed ID: 23708210
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Not Everyone Fits the Mold: Intratumor and Intertumor Heterogeneity and Innovative Cancer Drug Design and Development.
    Dzobo K; Senthebane DA; Thomford NE; Rowe A; Dandara C; Parker MI
    OMICS; 2018 Jan; 22(1):17-34. PubMed ID: 29356626
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Intratumor heterogeneity: nature and biological significance.
    Gerashchenko TS; Denisov EV; Litviakov NV; Zavyalova MV; Vtorushin SV; Tsyganov MM; Perelmuter VM; Cherdyntseva NV
    Biochemistry (Mosc); 2013 Nov; 78(11):1201-15. PubMed ID: 24460935
    [TBL] [Abstract][Full Text] [Related]  

  • 87. New insights from the widening homogeneity perspective to target intratumor heterogeneity.
    Tong M; Deng Z; Zhang X; He B; Yang M; Cheng W; Liu Q
    Cancer Commun (Lond); 2018 May; 38(1):17. PubMed ID: 29764517
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The challenge of intratumour heterogeneity in precision medicine.
    Seoane J; De Mattos-Arruda L
    J Intern Med; 2014 Jul; 276(1):41-51. PubMed ID: 24661605
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Intratumor heterogeneity in epigenetic patterns.
    Assenov Y; Brocks D; Gerhäuser C
    Semin Cancer Biol; 2018 Aug; 51():12-21. PubMed ID: 29366906
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Mass Spectrometry Imaging for the Investigation of Intratumor Heterogeneity.
    Balluff B; Hanselmann M; Heeren RM
    Adv Cancer Res; 2017; 134():201-230. PubMed ID: 28110651
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Clinical implications of intratumor heterogeneity: challenges and opportunities.
    Ramón Y Cajal S; Sesé M; Capdevila C; Aasen T; De Mattos-Arruda L; Diaz-Cano SJ; Hernández-Losa J; Castellví J
    J Mol Med (Berl); 2020 Feb; 98(2):161-177. PubMed ID: 31970428
    [TBL] [Abstract][Full Text] [Related]  

  • 92.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 93.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 94.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 95.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.